Jiya in an amended S-1 said it may issue a maximum of 11.5 million shares, which would generate up to $115 million in the offering. The SPAC is focused on biopharmaceutical companies. Read more.
Jiya Amends $100M IPO Prospectus
Related Posts
Riverstone’s Decarbonization Plus III Registers for $350M IPO
The renewables-focused SPAC plans to target a business in the energy and agriculture, industrials, transportation and commercial and residential sectors.
NorthView Acquisition Files Amended Proxy on Profusa Deal
Based in Emeryville, CA, Profusa “is pioneering the next generation of personalized medicine via the development of novel tissue-integrated biosensors. Profusa’s technology addresses the human body’s response to the presence of foreign material, enabling long-term monitoring of various biochemical parameters in real-time.”
Media SPAC Progress Acquisition Prices Upsized $150M IPO
The SPAC is interested in targets involved in cutting-edge media, entertainment and digital technology.
Temasek-Backed Vertex Set to be First SPAC to List in Singapore
The company, sponsored by state investor Temasek Holdings Pte.’s Vertex Venture Holdings Ltd., is offering 34 million units at S$5 each.